27 April 2023 - Several targeted agents for lung cancer approved through fast-track review due to their innovativeness and urgency ...
26 April 2023 - It takes the nation's drug-buying agency, PHARMAC, an average of 7.7 years to make funding decisions ...
21 April 2023 - The 2021-22 Stage 1 and Stage 2 PBS process improvements metrics report is now available. ...
20 April 2023 - Daiichi Sankyo today announced that the US FDA has extended the review period for the new ...
16 April 2023 - Australians are waiting two years longer to access new lifesaving subsidised medicines because of pharma giants. Now, ...
5 April 2023 - Safety and efficacy must be prioritised ahead of speed. ...
7 March 2023 - FDA extends PDUFA target action date to 30 June 2023. ...
24 February 2023 - Celltrion has come forward to explain reasons for the delayed approval of its Humira biosimilar, Yuflyma ...
20 February 2023 - Astellas Pharma today announced the US FDA notified the company that it is extending the original priority ...
17 February 2023 - Eisai anticipates about 100,000 patients diagnosed will be eligible for the drug by year three of its ...
16 February 2023 - EMA marketing authorisation application for leniolisib changed to standard review timetable. ...
10 February 2023 - Trent Zimmerman says it would be a mistake for Australia to narrow its health reform agenda ...
8 February 2023 - A process brought in to streamline decision-making around access to new medicines in NHSScotland during the ...
27 January 2023 - argenx today announced that the US FDA has extended the review of the biologics license application ...
26 January 2023 - The new deadline is 28 February 2023. ...